2019
Nursing Considerations for Patients Treated with Targeted Therapies
Goodwin K, Davies M. Nursing Considerations for Patients Treated with Targeted Therapies. 2019, 105-120. DOI: 10.1007/978-3-030-16550-5_9.Peer-Reviewed Original ResearchThe Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer
Andrews S, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. 2019, 65-84. DOI: 10.1007/978-3-030-16550-5_7.Peer-Reviewed Original Research
2001
Irinotecan and Taxane Combinations for Non–Small-Cell Lung Cancer
Murren J, Davies M. Irinotecan and Taxane Combinations for Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2001, 2: s20-s25. PMID: 14725726, DOI: 10.3816/clc.2001.s.004.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerAdvanced non-small cell lung cancerDay 1Treatment of NSCLCWeekly scheduleLow-grade gastrointestinal toxicitySmall cell lung cancerPaclitaxel-containing regimenDoses of docetaxelDose-limiting toxicityCell lung cancerEvaluable patientsNonhematologic toxicityStable diseaseGastrointestinal toxicityTaxane combinationsPartial responseProgressive diseaseMild diarrheaPreclinical modelsAdditive cytotoxicityToxicity profileTreatment scheduleChemotherapy